4.7 Review

Testosterone Therapy, Thrombophilia, Venous Thromboembolism, and Thrombotic Events

Journal

JOURNAL OF CLINICAL MEDICINE
Volume 8, Issue 1, Pages -

Publisher

MDPI
DOI: 10.3390/jcm8010011

Keywords

testosterone; thrombophilia; hypofibrinolysis; venous thromboembolism (VTE); Factor V Leiden heterozygosity; lupus anticoagulant; lipoprotein (a); thrombosis

Funding

  1. Lipoprotein Reseach Fund of the Jewish Hospital of Cincinnati

Ask authors/readers for more resources

In our sequential studies of 67 and 21 patients, testosterone therapy (TT) interacted with thrombophilia-hypofibrinolysis, leading to venous thromboembolism (VTE). Compared to 111 VTE controls not taking TT (VTE-no TT), the 67 and 21 cases were more likely (p < 0.05 for all) to have Factor V Leiden (FVL) heterogeneity (24% and 33% vs. 12%), the lupus anticoagulant (14% and 33% vs. 4%), and high lipoprotein(a) (33% vs. 13%, n = 21). After a first VTE and continuing TT, 11 thrombophilic cases had a second VTE despite adequate anticoagulation, 6 of whom, still anticoagulated, had a third VTE. The greatest density of thrombotic events was at three months after starting TT, with a rapid decline by 10 months. From <1 to 8 months after starting TT, 65% of VTE occurred, which may reflect TT-induced depletion of susceptible thrombophilic patients, leaving a winnowed residual group with fewer VTE events despite the continuation of TT. Before starting TT, we suggest screening for FVL, lipoprotein(a), and the lupus anticoagulant to identify patients at increased VTE risk, with an adverse risk-to-benefit ratio for TT. We suggest that TT should not be started in patients with known thrombophilia-hypofibrinolysis, and should not be continued after a first VTE. When TT is given to patients with thrombophilia-hypofibrinolysis, VTE may occur and then recur despite adequate anticoagulation.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available